Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Killer Cell Lectin Like Receptor C1 (NKG2A)
- Target
- NKG2A
- Molecular classification
- Killer cell lectin-like receptor family, CD molecules, Type II transmembrane protein, Receptor
01
Overview
Killer cell lectin-like receptor C1 (NKG2A) is an inhibitory receptor expressed on natural killer (NK) cells and some cytotoxic T lymphocytes. It forms a heterodimer with CD94 and recognizes HLA-E presenting peptides derived from the leader sequences of MHC class I molecules. This interaction delivers inhibitory signals that suppress NK cell activation against normal "self" targets. NKG2A is a therapeutic target in cancer immunotherapy, with antibodies like monalizumab being developed to block its inhibitory function and enhance NK cell-mediated killing of tumor cells.
- Other names
- CD159aKLRC1killer cell lectin-like receptor subfamily C, member 1
02
Mechanism of action
Antibody blockade of NKG2A, preventing its interaction with HLA-E and thus relieving inhibition of NK cell activity
03
Biological functions
Immune responseInhibitory checkpoint receptorSelf-nonself discriminationRegulation of NK cell cytotoxicity
04
Disease associations
Natural killer cell deficiencySenile entropionCancer
05
Safety considerations
Potential for autoimmunity or increased susceptibility to infection due to broad immune activation
06
Interacting drugs
Monalizumab
07
Biomarkers
HLA-E expression levels (as predictor of response)NKG2A expression levels (as predictor of response)
Beyond the preview
Go deeper on Killer Cell Lectin Like Receptor C1 (NKG2A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Killer Cell Lectin Like Receptor C1 (NKG2A).